BioAge Labs (BIOA) Cash from Investing Activities (2024 - 2026)

BioAge Labs has disclosed Cash from Investing Activities across 3 years of filings, most recently posting -$46.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$46.8 million, up 40.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$64.0 million (up 18.34% YoY), and the FY2025 annual result was -$95.2 million, down 25915.3% from the prior year.
• Cash from Investing Activities came in at -$46.8 million for Q1 2026 at BioAge Labs, down from -$14.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $12.8 million in Q3 2025 to a low of -$78.0 million in Q1 2025.
• The 3-year median for Cash from Investing Activities is -$7.4 million (2024), against an average of -$17.8 million.
• Peak annual rise in Cash from Investing Activities reached 4310.16% in 2025, while the deepest fall reached 55392.31% in 2025.
• BioAge Labs' Cash from Investing Activities stood at -$26000.0 in 2024, then plunged by 55392.31% to -$14.4 million in 2025, then tumbled by 224.04% to -$46.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$46.8 million (Q1 2026), -$14.4 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.